Canada's patent term restoration regime has been up and
running for over a year and a half. As of the end of April 2019,
there have been 38 applications filed, and 29 granted; seven have
been refused and the remainder are pending. The regime seems to be
effective for those companies that are able to file their drug
submissions in Canada within a year of the first filing in other
major jurisdictions.
This one-year deadline is seen as the major impediment for
companies that are trying to take advantage of this regime. For
many larger companies, it appears that they have been able to move
resources around and change their filing strategy in order to meet
this deadline, however, smaller biotechnology and pharmaceutical
companies do not necessarily have the resources to dedicate to
filing in multiple jurisdictions before they have approval in a
major market, such as the U.S. or Europe.